Nereus Pharmaceuticals Announces Keith Bostian Joins Its Scientific Advisory Board.Business Editors and Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2002 Nereus Pharmaceuticals Inc., a pioneer in drug discovery and development from marine microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. sources, today announced that it has appointed Keith Bostian, Ph.D. to its scientific advisory board. Dr. Bostian will also act as an executive consultant to the company. Bostian is a scientist with an entrepreneurial background who founded two biotech companies. He was the founder and chief executive officer of Iconix Pharmaceuticals, Inc., a leader in the emerging field of chemogenomics, and is currently a member of the company's board of directors. Prior to this, Bostian was a founder and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Microcide Pharmaceuticals, Inc., now Essential Therapeutics, Inc., a development-stage pharmaceutical company with clinical and pre-clinical programs focused on hematology, oncology, and infectious diseases infectious diseases: see communicable diseases. . Before Microcide, he was head of microbiology and molecular genetics molecular genetics n. The branch of genetics that deals with hereditary transmission and variation on the molecular level. at Merck & Co., where he was responsible for antimicrobial research and new leads from natural products for all of Merck's worldwide drug discovery programs. "We are honored to have Dr. Bostian on our scientific advisory board. His breadth and depth of experience in oncology, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and natural products research significantly enhances Nereus' development capabilities," said Kobi Sethna, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Nereus. "He will be a tremendous asset to us as we continue to identify exciting compounds and eventually develop new medicines from marine microbes." Bostian is an inventor on numerous patents in drug discovery and genomics, and has led efforts resulting in numerous clinical candidates, one leading to a new class of anti-fungal antibiotics, Cancidas(R). He has served on numerous advisory and editorial boards and is a fellow of the American Academy for Microbiology. He was a member of the faculty at Brown University, as assistant and associate professor, and as an American Cancer Society American Cancer Society, n.pr established in 1913, this national volunteer-based health organization is committed to the elimination of cancer through prevention and treatment and to diminishing cancer suffering through advocacy, scholarship, research, Postdoctoral Fellow, he did postdoctoral research at the University of Massachusetts The system includes UMass Amherst, UMass Boston, UMass Dartmouth (affiliated with Cape Cod Community College), UMass Lowell, and the UMass Medical School. It also has an online school called UMassOnline. Medical Center and at Brandeis University with Harlyn O. Halvorson. Bostian earned his doctorate in biochemistry from the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies . "I am pleased to join Nereus' scientific advisory board, which offers the company a wide range of expertise, from cancer and infectious diseases research to natural products and microbiology," said Bostian. "Nereus' discovery and development efforts utilizing untapped sources of chemical diversity will provide an uninterrupted pipeline of novel drug candidates to treat infectious diseases, cancer and inflammation. I am eager to lend my expertise to the effort." About Nereus Pharmaceuticals, Inc. Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity. With unmatched expertise in marine microbiology and structural elucidation, Nereus is using its integrated platform technologies to identify novel biologically active compounds. The company believes that its marine microbes will be the next great source of drug discovery for the pharmaceutical industry. Nereus aims to develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. The company is privately held and based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . For more information, visit www.nereuspharm.com. Nereus and the stylized styl·ize tr.v. styl·ized, styl·iz·ing, styl·iz·es 1. To restrict or make conform to a particular style. 2. To represent conventionally; conventionalize. N are registered trademarks of Nereus Pharmaceuticals, Inc. All other product and company names may be registered trademark or trademarks of their respective owners. Except for the historical information contained herein, this press release contains forward-looking statements, including statements containing the words "intends," "expects," and similar words. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the company's actual results to be materially different from historical results or any results expressed or implied by such forward-looking statements. We assume no obligation to update any forward-looking statements to reflect events or circumstances arising after the date hereof. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion